Drug Profile
Research programme: apolipoprotein A1 deficiency therapeutics - Amsterdam Molecular Therapeutics
Alternative Names: AMT-050Latest Information Update: 16 Jul 2012
Price :
$50
*
At a glance
- Originator Amsterdam Molecular Therapeutics
- Class
- Mechanism of Action Apolipoprotein A I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lipid metabolism disorders
Most Recent Events
- 18 Nov 2009 No development reported - Preclinical for Lipid metabolism disorders in Europe (unspecified route)
- 14 Aug 2007 Preclinical trials in Lipid metabolism disorders in Europe (unspecified route)